E15. Use of micro-array analysis to predict outcome and response in breast cancer patients  by unknown
E15. Use of microarray analysis to predict outcome and response
in breast cancer patients
Els M.J.J. Berns *
Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Josephine Nefkens Institute,
Room Be424, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
Breast cancer is diagnosed one million times every
year worldwide. It is a clinically heterogeneous disease,
as evidenced by widely variable morphological appear-
ances, distinctive gene expression proﬁles and diﬀerent
responses to therapies. For breast cancer patients, the
accuracy with which the progress of their disease can be
mapped will make the diﬀerence between whether they
are over- or under-treated. Deﬁning which patients will
respond to therapy impacts upon treatment outcome
and patients’ survival.
The current prognostic criteria used for breast cancer
include age, tumour size, axillary-node status, histolo-
gical type, pathological grade and hormone–receptor
status. Initially, human breast cancers depend on oes-
trogens for their development and progression. Ap-
proximately 75% express the classical oestrogen receptor
(ER-a), which is an important target for therapy. En-
docrine strategies that interfere with the action of nat-
ural hormones have been developed and given to
patients as adjuvant treatment of their primary cancer
or for treatment of metastatic breast cancer, as well as
for the prevention of breast cancer in women at high-
risk. The proven classical selective oestrogen receptor
modulator (SERM) is tamoxifen (reviewed by Jordan in
Ref. [1]). Nevertheless, in women with metastatic breast
cancer, endocrine therapies produce response rates of
only 30% in unselected patients and of approximately
50% in women with ER-a-positive tumours. By contrast,
only 5–10% of ER-a-negative tumours will respond fa-
vourable to hormonal treatments.
In recent years, gene expression investigations have
developed from the analysis of a single gene to that of
ten of thousands of genes per experiment. This so-called
high-throughput gene analysis or gene expression pro-
ﬁling makes use of speciﬁc oligonucleotides or cloned
cDNA fragments spotted on a glass slide (micro-array).
In 2000, Hanahan and Weinberg [2] proposed, ‘‘The
growth regulation within a tumour can only be ex-
plained once we understand the contributions of the
ancillary cells present in a tumour – the apparently
normal bystanders such as ﬁbroblasts and endothelial
cells – which must play key roles in driving tumour cell
proliferation’’. This means that knowledge of the inter-
actions of malignant cells with neighbouring cells within
a tumour environment is critical to understand the
processes involved in breast cancer metastasis or its
progression to therapy-resistance. Current studies of
gene expression proﬁling on clinical samples or model
systems show the enormous impact that expression
proﬁling can have on our understanding of various
biological processes in well-deﬁned tumour models or
selected clinical specimens (for reviews see [3]). The
analysis of the overwhelming body of data was initially
guided through the identiﬁcation of ‘‘clusters’’ of genes
showing similar patterns of expression by using algo-
rithms and software described by Eisen in [4]. More
recently, several other statistical approaches that pro-
vide additional information are applied, although rules
of evidence for marker discovery and validation have
not yet been fully developed [4,5].
Using RNA isolated from human breast tumours and
from normal breast tissue, and by comparison with
those expression proﬁles obtained for mammary epi-
thelial cell lines grown in vitro, the expression proﬁles for
some of the clusters of co-expressed genes in the tumour
samples could be attributed to speciﬁc cell types,
including stromal cells and B lymphocytes. This means
that gene expression patterns in tumours have
recognisable counterparts in speciﬁc cells, reﬂecting
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the tumour epithelial, stromal and inﬂammatory
components of the tumour tissue. Unsurprisingly, two
main subgroups of breast cancers have been identiﬁed
by gene expression proﬁling; the ER-a-positive and
-negative subsets [6]. Interestingly, relevant information
on tissue specimens of various cancer subtypes can be
extracted from the proﬁles as well. This has led to im-
proved tumour classiﬁcations. For example, Hedenfalk
and colleagues [7] and our Group [8] were able to dis-
tinguish BRCA1- and BRCA2-mutated tumours from
sporadic breast cancer cases. Moreover, speciﬁc gene
expression patterns were found to be predictive of dis-
ease outcome for breast cancer patients [9]. The collea-
gues at the Dutch Cancer Institute, for example, used a
previously established 70-gene prognotic proﬁle to
classify patients with primary breast cancer into poor-
and good-prognotic groups. They showed that (in young
breast cancer patients, i.e. those patients younger than
53 years of age with stage I or II disease) this proﬁle is a
more powerful predictor of disease outcome than stan-
dard systems based on clinical and histological criteria.
They proposed that this more accurate means of prog-
nostication in breast cancer will improve the selection of
patients for adjuvant systemic therapy [9,10]. If vali-
dated by others and in larger series, the diﬀerences in
gene expression proﬁling may become a widespread
strategy in the future for predicting clinical outcome.
Another potential application of gene expression
proﬁling involves studies of the expression of particular
genes in relation to mechanisms of drug sensitivity and
resistance. As described above, there is a clinical ne-
cessity to distinguish an individual patient who will
beneﬁt or fail from endocrine treatment, whether ap-
plied as adjuvant therapy or for advanced disease.
Molecular proﬁling of a panel of breast tumour tissues
from a well-deﬁned group patients who received anti-
oestrogens as ﬁrst-line treatment for advanced disease
with known clinical follow-up, oﬀers a unique oppor-
tunity to link the expression of large numbers of genes
to the type of response. Our department has gathered
together information on a huge panel of frozen breast
tumours from patients who have well-deﬁned responses
and clinical follow-up in a computerised database,
thereby allowing this type of unique study. For ex-
ample, we have shown in large sample cohorts that the
urokinase plasminogen activator (uPA) pathway, TP53
and vascular endothelial growth factor (VEGF) are
predictors of response to tamoxifen. We also used glass
arrays with approximately 18 000 spotted human
cDNAs to identify a set of genes whose expression
pattern predicts the type of response to anti-oestrogen
therapy. At present, we have identiﬁed and validated a
set of classiﬁer genes that can distinguish primary
breast tumours from patients who responded and from
those who did not respond to anti-oestrogen treatment
[11].
The identiﬁcation of new genes will also allow me-
chanistic studies aimed at the development of new ef-
fective treatment strategies, such as combination
therapy with an anti-oestrogen and a drug interfering
with one of the pathways that may have been activated
during hormone-independent tumour growth. More-
over, molecular proﬁling of a breast cancer tissue sample
obtained by ﬁne-needle or through-cut biopsy from
patients included in prospective trials may be feasible in
the near future. These studies could involve patients
with advanced breast cancer, but also patients with
primary breast cancer who may beneﬁt from adjuvant
treatment. Ultimately, micro-arrays will be developed
that can be used for future diagnostic purposes: to
predict the type of response to therapy on an individual
breast cancer patient basis.
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